Team of Five Labs Launches Novel Attack on ALS Amyotrophic Lateral Sclerosis (ALS) can arise from aberrant genes. A group of five Brown University professors proposes that a cure may also come from aberrant genes – genetic mutations that suppress ALS. A new research grant supports their comprehensive investigation of ALS in flies, worms, mice and human cells.

Progress Coming in Amyotrophic Lateral Sclerosis, but Rigorous Studies Needed The community of individuals living with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, has endured many false hopes for promising therapies and is still waiting for the first disease-modifying drug. Nevertheless, "we have made huge progress in the last decade in ALS," Merit Cudkowicz, professor of neurology at Harvard Medical School and chief of the neurology service and director of the MDA ALS clinic at Massachusetts General Hospital, told participants in an integrated neuroscience session on ALS at the American Academy of Neurology... READ MORE [...]

Johns Hopkins University, Cedars-Sinai and Massachusetts General Hospital Announce Groundbreaking ALS Research Project of Answer ALS Research Designed to Fully Understand and Defeat ALS; “Big Data” Technology Will Drive Unprecedented Analysis Capability $20 Million in Funding from Committed Team of Donors, including the National Football League, the PGA TOUR, ALS Finding a Cure (a project of the Leandro P. Rizzuto Foundation), Travelers, The Fishman Family and The Bari Lipp Foundation BALTIMORE, LOS ANGELES and BOSTON, September 9, 2015 – Johns Hopkins University’s Robert Packard Center for ALS Research, Cedars-Sinai Medical Center’s Regenerative Medicine Institute and the Massachusetts General Hospital Neurological [...]

Karyopharm Advancing Neuroprotective SINE™ Compounds in Amyotrophic Lateral Sclerosis (ALS) Preclinical efficacy of SINE™ compounds validated in journal Nature publication–  Presentations of ALS abstracts at upcoming AAN and SfN meetings – Collaborator grant funding supports Karyopharm’s ALS research– Newton, Mass. – September 3, 2015 – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported that its SINE™ nuclear transport compounds are being evaluated for the treatment of Amyotrophic Lateral Sclerosis (ALS) and that preclinical data abstracts will be presented at two upcoming neuroscience meetings. A recent publication appearing in the journal Nature confirmed that nuclear transport is disrupted in [...]